BioTalk US 2022 Online Evaluation Form Global Market Summits values your feedback on your experience of the BioTalk US 2022 Online.Please complete this form to share your experience 2022 Event feedback Form Name*Company Name*Please provide a brief description of your experience at the BioTalk US 2022*Would you recommend BioTalk US 2022 to your colleagues?* Yes No Did the sessions you attended meet your expectations?*What would make it a more valuable experience?*PROGRAMMEHow would you rate the different sessions you attended?Day 1 Automated, Integrated, Modular Systems for the Manufacturing of Biopharmaceutical Drug Products (Richard D. Braatz, Edwin R. Gilliland Professor of Chemical Engineering, Massachusetts Institute of Technology (MIT))ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):MES and Automation: A Combination That Drives Digital Transformation (Chris Rickey, Principal Engineer, Global Technical Lead- MES/MOM/PLM, Rockwell Automation )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Next Frontiers in Biologics Process Development (Ujjwal Bhaskar, Associate Director, Global Downstream Biologics Development, Bristol Myers Squibb )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Minimizing Delays to Manufacturing of a Complement MAb Fusion Protein During a Pandemic (Theresa Carbeau, Associate Director, Process Development, Q32 Bio / Andy Quach, Scientist II, Process Development, Q32 Bio)ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Filtrox: Optimisation of the “mid-stream” filtration process step in biopharmaceutical productionExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Purolite: The Current Production of Jetted ResinExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Holistic Approach to a Pilot-Scale Development Laboratory Upgrade (Kristin O’Neil, Principal Scientist, Bioprocess Development, Merck)ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Speed to IND: Downstream process development strategies and solutions to deliver novel multi-specific biologics to the clinic (Yekaterina Lin, Associate Director, Purification, AbbVie )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Leveraging computational fluid dynamics for biopharmaceutical development (Chadakarn Sirasitthichoke, Manager, Process Engineer MSAT, BMS )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Platforming the protein-A capture step using multi-column chromatography for clinical manufacturing (Kevin Carrigan, Associate Director, Pilot Plant, Takeda )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):In silico design of a commercial-scale bioreactor using Computational Fluid Dynamics (CFD)(Iman Mirzaee, Sr. Manager – Data Sciences, Amgen )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Smart Process Data Analytics for Biopharmaceutical Manufacturing (Richard D. Braatz, Edwin R. Gilliland Professor of Chemical Engineering, Massachusetts Institute of Technology (MIT))ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Burkert: The “why and how” behind the rapid growth and development of single-use biopharmaceutical manufacturingExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Waters: Accelerating upstream process development with direct CQA and media analysis feedbackExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Aspentech: Using First Principles Models to Accelerate Design and Scale-up in Upstream FermentationExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Open Panel Discussion: The CMC challenges of innovative biological therapiesExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Open Panel Discussion: Current Advances in Continuous ManufacturingExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Day 2 Consistently Providing Viral Clearance Capability in Bispecific Antibody Manufacturing Process (Ji Zheng, Director of Biologics Development, Product Development, Global Product Supply, BMS )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Ensuring virus filtration scalability and optimal performance in manufacturing (Daniel Strauss, R&D Director, Asahi Kasei BioProcess America )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Enabling Downstream Continuous Processing with a Fully Automated and Integrated System for Pilot and Clinical Manufacturing scales (Irina Ramos, Director in Bioprocess Technologies & Engineering group, AstraZeneca )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Zeta: Ambitious Realistic and Business-Friendly: Holistic Approaches to Decarbonization in the Pharmaceutical IndustryExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Cell Tainer BIOTECH BV: Scale-up / scale-down aspects of single-use bioreactorsExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Sotio: Introduction to CAR-T and the BOXR Platform (Geoffrey Hodge, Chief Executive Office, SOTIO Biotech US)ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Roundtable Discussions:ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Application of QbD principles through product life cycle (Balrina Gupta, Director, Uptream Operations and Technologies, Merck)ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Process characterization and PPQ control strategy definition for AAV gene therapy (Chao Huang, Downstream Process Development Director, Ultragenyx )ExcellentVery GoodGoodFairPoorAdditional Comment (Optional):Open Panel Discussion: Strategic Outsourcing and Effective Tech Transfer in CMC DevelopmentExcellentVery GoodGoodFairPoorAdditional Comment (Optional):
